Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1315-1323

  Szczuraszek, Katarzyna ^a   Materna, Verena ^b   Halon, Agnieszka ^a   Mazur, Grzegorz ^a   Wróbel, Tomasz ^a   Kuliczkowski, Kazimierz ^a   Maciejczyk, Adam ^c   Zabel, Maciej ^a,d   Drag, Marcin ^e,f   Dietel, Manfred ^b   Lage, Hermann ^b   Surowiak, Pawel ^a,b,c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^f BURNHAM INSTITUTE   (United States)

Author keywords

ABC transporters; Cyclooxygenase 2; Hodgkin's lymphomas

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CYCLOOXYGENASE 2; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2;

ADULT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS;

EID: 70449375154     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000570     Document Type: Article

References (23)

1. Shipp MA, Harrington DP, Anderson JR and Armitage JO: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-992, 1993.
2. Lage H: An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 65: 3145-3167, 2008.
3. Patel VA, Dunn MJ and Sorokin A: Regulaction of MDR-1 (P-glycoprotein) by Cyclooxygenase-2. J Biol Chem 277: 38915-38920, 2002.
4. Surowiak P, Materna V, Denkert C, Kaplenko I, Spaczynski M, Dietel M, Zabel M and Lage H: Significance of cyclooxygenase 2 and MDR1/ P-glycoprotein coexpression in ovarian cancers. Cancer Lett 235: 272-280, 2006.
5. Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert C, Zabel M and Lage H: Relationship between cyclooxygenase 2 and P-glycoprotein expressions in invasive breast cancers and their prognostic significance. Breast Cancer Res 7: R862-R870, 2005.
6. Gasparini G, Longo R, Sarmiento R and Morabito A: Inhibitor of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 4: 605-615, 2003.
7. Kim SK, Lim SY, Wang KCh, Kim YY, Chi JG, Choi YL, Shin HJ and Cho BK: Overexpression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in vitro. Oncol Rep 12: 403-409, 2004.
8. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC and Tangrea JA: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multi-drug resistance possible? Anticancer Res 21: 2141-2147, 2001.
9. Ziemann Ch, Schäfer D, Rüdell G, Kahl GF and Hirsch-Ernst KI: The cyclooxygenase system participates in functional Mdr1b overexpression in primary rat hepatocyte cultures. Hepatology 35: 579-588, 2002.
10. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M and Lage H: ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res 12: 7149-7158, 2006.
11. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathology 8: 138-140, 1987.
12. Ristimäki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S and Haglund C: Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 158: 849-853, 2001.
13. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and Dubois RN: Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
14. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S: Expression of prostaglandin G/H synthase-1 and -2 in human colon cancer. Cancer Res 55: 2556-2559, 1995.
15. Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A, Berger F, Kluin P, Ott G, Pileri S, Pedrinis E, Feller AC, Merz H, Janssen D, Hansmann ML, Krieken H, Moller P, Stein H, Unterhalt M, Hiddemann W and Parwaresch R: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 131: 29-38, 2005.
16. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT and Fahey III TJ: Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. Cancer Res 59: 987-990, 1999.
17. Filipits M, Jaeger U, Simonitsch I, Chzzali-Bonfadin C, Heinzl H and Piker R: Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas. Clin Cancer Res 6: 3417-3423, 2000.
18. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR and Willman CL: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology group Study. Blood 94: 1086-1099, 1999.
19. Zhan Z, Sandor VA, Gamelin E, Regis J, Dickstein B, Wilson W, Fojo AT and Bates SE: Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. Blood 89: 3795-3800, 1997.
20. Ohsawa M, Ikura Y, Fukushima H, Shirai N, Sugama Y, Siekane T, Hirayama M, Hino M and Ueda M: Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 68: 422-431, 2005.
21. Fantappie O, Masini E, Sardi I, Raimondi L, Bani D, Solazzo M, Vannacci A and Mazzanti R: The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatol 35: 843-852, 2002.
22. Renes J, de Vries EGE, Jansen PLM and Müller M: The (patho)physiological functions of the MRP family. Drug Res Updates 3: 289-302, 2000.
23. Kang HK, Lee E, Pyo H and Lim SJ: Cyclooxygenase-independent down-regulation of multidrug resistance-associated protei-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 4: 1358-1363, 2005.